A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer
NCT ID: NCT04970264
Last Updated: 2021-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
2000 participants
OBSERVATIONAL
2020-04-01
2025-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We expect to enroll 2000 young breast cancer patients (≤35 years old). All patients were detected by targeted next generation sequencing (NGS)(600+ gene panel). Clinical diagnosis, treatment and prognosis information were collected. The Stratification factors mainly include stage, molecular type and treatment method.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Comparing the Differences Between Young and Non-young Breast Cancer
NCT06793306
Evaluation of Prognostic Monitoring for Young Breast Cancer Patients
NCT04145986
A Study for Dynamic Prediction Model of Breast Cancer Bone Metastases
NCT06544668
Patterns of Breast Cancer Management and Prognosis of Breast Cancer in China
NCT04076111
A Multicenter Prospective Observational Cohort Based on a Breast Cancer Medical Record Database in China
NCT06591039
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients were required to sign informed consent before entering the group. All updated versions of informed consent and written information will be provided to the subjects during the participant's participation.
In the experimental design stage, the statistical principle was used to make reasonable and effective arrangements for the relevant factors. Employ statistical experts to calculate the sample size and data statistics, and participate in the design process. Data collection and follow-up were conducted by specially assigned personnel, professional doctors were assigned to conduct data review regularly, and special data management personnel were provided. They will ensure the authenticity, reliability and security of data throughout the process.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. The age of diagnosis was 18-35 years old.
3. ECOG score was 0-2, and the expected survival time was more than 3 months.
4. No serious complications; no liver, kidney, hematopoiesis dysfunction.
5. Informed consent, and patients willing to long-term follow-up. -
Exclusion Criteria
2. Having a clear history of neurological or mental disorders (including epilepsy or dementia).
3. Patients have uncontrollable complications, including active infection, symptomatic congestive heart failure, unstable angina pectoris, arrhythmia, decompensated diabetes, uncontrollable hypertension or mental disorders.
4. Pregnant or lactating female patients.
5. HIV infected patients.
6. Patients with other tumors.
7. After comprehensive evaluation, the researchers believe that patients are not suitable for this study.
18 Years
35 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Medical University Cancer Institute and Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TianJin Medical University Cancer Institute and Hospital
Tianjin, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
YWBC-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.